Drug intelligence / Profile preview

JOYFINAC-EP

Development stage
Unknown
Lead developer
JoY Pharma
Modality
Small Molecules
Administration
Oral
01

Overview

JOYFINAC-EP is a branded generic fixed-dose combination (FDC) medication marketed by JoY Pharma, an Indian pharmaceutical company. It is specifically indicated for the treatment of pain and inflammation associated with musculoskeletal disorders where muscle spasms are a complicating factor. The formulation combines two active ingredients: aceclofenac and eperisone. Aceclofenac is a non-steroidal anti-inflammatory drug (NSAID) that provides analgesic and anti-inflammatory effects by inhibiting the cyclooxygenase enzymes (COX-1 and COX-2), thereby reducing the synthesis of pro-inflammatory prostaglandins. Eperisone is a centrally acting skeletal muscle relaxant that works by inhibiting spinal reflexes and relaxing both skeletal and vascular smooth muscles through the blockade of voltage-gated calcium and sodium channels. This dual action helps to alleviate pain while simultaneously reducing muscle stiffness and improving local circulation.

Brand names
JOYFINAC-EP
Other names
Aceclofenac + Eperisone
02

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)CaV (Voltage-gated calcium channel protein complex)PGHS-1 (Prostaglandin G/H Synthase 1)NaV (Voltage-gated sodium channels)

Beyond the preview

Go deeper on JOYFINAC-EP.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on JOYFINAC-EP.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call